ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

MPM Capital

Hunt Technology Ventures

Vida Ventures

Colt Ventures

OrbiMed

OUP (Osage University Partners)

Leaps by Bayer

Solasta Ventures

Bioluminescence Ventures

EcoR1 Capital

Pfizer Venture Investments

Sanofi Ventures

Amgen Ventures

Tekla Capital Management

NS Investment

Matrix Capital Management

Cystic Fibrosis Foundation

ReCode Therapeutics

We're thrilled to announce that the first patient has been dosed in our Phase 1 clinical trial of RCT1100, a novel mRNA-based medicine for patients with primary ciliary dyskinesia (PCD) caused by DNAI1 gene mutations.

This marks a significant step in our efforts to bring innovative therapies to PCD patients who currently have no approved treatment options. RCT1100, developed using our proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform, is designed to restore ciliary function by targeting the disease's root cause.

As we advance this trial, we extend our heartfelt thanks to the PCD community for their ongoing support. Stay tuned for more updates on this groundbreaking journey!

Learn more at https://ThinkPCD.com, and read the full press release here:
https://lnkd.in/guA6BSGR

#pcd #geneticmedicines #patientsfirst #PCDfoundation

As we welcome the New Year, all of us at ReCode Therapeutics are filled with excitement and optimism. 2024 marks not just a change in the calendar but a renewed opportunity for discovery and innovation in our quest to transform the lives of those living with genetic diseases.

We send our well wishes for a year filled with health, happiness, and achievement. To a joyous and prosperous New Year!

As the holiday season unfolds, ReCode Therapeutics extends our warmest wishes to our community, partners, and the families we serve. This time of year reminds us of the importance of connection and compassion.

May this season bring joy, peace, and rejuvenation to you and your loved ones. 

Happy Holidays to all!

#HappyHolidays #TeamReCode

Join the ReCode Therapeutics team, where your passions and drive find a welcoming home. Here, our mantra is clear: "Patients first, always." 

But we're about more than just our platforms. At ReCode, we cultivate an environment where imagination flourishes, passions are fueled, and every voice is heard and valued. Our dedication to diversity and inclusivity has proudly earned us Best Place to Work recognition by the San Francisco Business Times and Silicon Valley Business Journal.

Whether you're a seasoned scientist or a nascent graduate, we have an array of opportunities across various disciplines.

ReCode Your Future:
https://recodetx.com/careers/

#CareerOpportunities #BPTW #PatientFirst

Viewport Meta

IPhone / Mobile Compatible

Google Tag Manager

Google Font API

Google Analytics

DoubleClick.Net

US Privacy User Signal Mechanism

Microsoft Exchange Online

Office 365 Mail

Business Management

David Lockhart

Senior Vice President and Head of Business Development

Angele Maki

Engineering

Arunan Kaliyaperumal

Vice President Clinical Research

Jonathan Steinfeld

Finance and Administration

Marc Posel

Legal

Max Barker

Senior Vice President, CMC

Vladimir Kharitonov

Alyce Lichaa

Director, Accounting & Assistant Controller

Carol Wolf

Operations

DeJuan Owens

Rana Al-Hallaq

Helen S. Kim

Kouki Harasaki

Michael Torres

Shehnaaz Suliman

Peter Thompson

Rakhshita Dhar

Daniel Siegwart

Co-Founder

Philip Thomas

CEO & Board Member

Nicholas P. France

Senior Vice President of Clinical Development

John Matthews

President & CSO

Biopharma Companies

Pharmaceutical Companies With Less Than $50M in Revenue (Top 10K)

Southern US Pharmaceutical Companies

Therapeutics Companies (Top 10K)

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. Its selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The company aims to leverage innovative technologies to provide solutions for individuals affected by genetic diseases.

Venture Round - ReCode Therapeutics

Series B - ReCode Therapeutics

Series A - ReCode Therapeutics

Seed Round - ReCode Therapeutics

Dallas

Texas

United States

North America

Recode Therapeutics Secures $15 Million in Funding

Cystic fibrosis: Five biotechs breathing life into the therapeutic space

ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia

Lung-targeting lipid nanoparticles with CRISPR components successfully treat cystic fibrosis mouse models

New Article Published in Science Highlights the Potential of ReCode Therapeutics' Systemic Lung Delivery and CFTR ...

ReCode Therapeutics on LinkedIn: #clinicaltrials #primaryciliarydyskinesia #pcd

ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors

A lipid nanoparticle delivery system designed to target specific organs and bypass the liver, enabling the delivery of various genetic medicines.

An inhaled mRNA therapy for Primary Ciliary Dyskinesia, currently in Phase 1 clinical development.

An inhaled mRNA therapy targeting Cystic Fibrosis caused by Class I mutations, set to enter clinical trials in early 2024.

Therapeutics aimed at correcting genetic diseases across a range of conditions including musculoskeletal, CNS, liver, and infectious diseases.

The Netherlands

Europe

India

Asia

Germany

Biotech company focusing on small RNA technologies, diagnostics, biomarker detection, and RNAi-based therapeutics.

Somagenics

ReCode Therapeutics is a private company founded in 2015 in the USA. The company develops precision genetic medicines using a proprietary delivery platform for the treatment of various genetic diseases, including cystic fibrosis and primary ciliary dyskinesia. ReCode Therapeutics is a multi-platform company developing non-viral nanoparticles for the delivery of diverse RNA- and protein-based therapeutics to targeted tissues and first-in-class tRNA NanoCorrectors for the correction of nonsense mutations causing cystic fibrosis and other diseases.

news impact assignment basic	general	Feb 21, 2024 3:42 PM	5a7c5682
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 21, 2024 3:42 PM	abb9e0d4
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	960a76e7
crunchbase profile	general	Nov 25, 2024 11:34 AM	0c11f9c6
li profile	general	Feb 21, 2024 3:42 PM	45774c49
translate crunchbase fundingrounds	general	Nov 25, 2024 2:15 PM	f471fb8b
peers	general	Feb 21, 2024 3:42 PM	d9d78b90
news basic	general	Feb 21, 2024 3:42 PM	c9c3c7c5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:RECODETX

ReCode Therapeutics